These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17416456)

  • 1. The long-term outcome of medical therapy for BPH.
    Madersbacher S; Marszalek M; Lackner J; Berger P; Schatzl G
    Eur Urol; 2007 Jun; 51(6):1522-33. PubMed ID: 17416456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug therapy for benign prostatic syndrome (BPS)].
    Berges R
    Aktuelle Urol; 2006 Sep; 37(5):351-62. PubMed ID: 17004180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Benign prostatic hyperplasia: medical therapy].
    Schlenker B; Gratzke C; Weidlich P; Seitz M; Reich O; Stief CG
    MMW Fortschr Med; 2007 Aug; 149(33-34):29-31; quiz 32. PubMed ID: 17912863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of medical treatment in benign prostatic hyperplasia.
    Kim CI; Chang HS; Kim BK; Park CH
    Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the combination of an alpha1-adrenergic antagonist with a 5alpha-reductase inhibitor improve urinary symptoms more than either monotherapy?
    Hollingsworth JM; Wei JT
    Curr Opin Urol; 2010 Jan; 20(1):1-6. PubMed ID: 19881352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification for benign prostatic hyperplasia (BPH) treatment.
    Emberton M; Fitzpatrick JM; Rees J
    BJU Int; 2011 Mar; 107(6):876-80. PubMed ID: 21265993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5alpha-reductase inhibition for men with enlarged prostate.
    Issa MM; Kraft KH
    J Am Acad Nurse Pract; 2007 Aug; 19(8):398-407. PubMed ID: 17655569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms in the alpha1A-adrenoceptor gene do not modify the short- and long-term efficacy of alpha1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.
    Mochtar CA; Laan W; Van Houwelingen KP; Franke B; De La Rosette JJ; Schalken JA; Kiemeney LA
    BJU Int; 2006 Apr; 97(4):852-5. PubMed ID: 16536786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent progress in the medical treatment of benign prostatic hyperplasia].
    Cornu JN; Rouprêt M
    Prog Urol; 2007 Sep; 17(5 Suppl 1):1029-32. PubMed ID: 17969785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
    Siami P; Roehrborn CG; Barkin J; Damiao R; Wyczolkowski M; Duggan A; Major-Walker K; Morrill BB;
    Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary patients with LUTS/BPH requiring prostatectomy have long-term history of treatment with alpha1-blockers and large prostates compared with past cases.
    Takeuchi M; Masumori N; Tsukamoto T
    Urology; 2009 Sep; 74(3):606-9. PubMed ID: 19586655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medical therapy of benign prostatic hyperplasia].
    Altarac S
    Lijec Vjesn; 2005; 127(11-12):316-23. PubMed ID: 16583940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.